Aptamer Discovery

Aptamer Discovery encompasses systematic processes identifying single-stranded nucleic acid sequences with high affinity for target molecules through iterative in vitro selection cycles known as SELEX. These molecular recognition elements emerge from screening vast oligonucleotide libraries against proteins, small molecules, cells, and pathogens through rounds of selection and amplification.

The biopharmaceutical industry employs aptamer discovery for developing novel diagnostics, therapeutics, and research tools offering antibody-like targeting with distinct manufacturing advantages. Automated SELEX platforms accelerate discovery through robotic selection cycles and next-generation sequencing analysis of enriched libraries. Cell-SELEX generates aptamers targeting live cell surface molecules enabling cancer cell-specific binding. Modified nucleotides incorporated during selection improve aptamer stability. Negative selection against related targets removes cross-reactive sequences improving specificity. As aptamer chemistry advances, discovery campaigns increasingly integrate computational prediction enabling rapid generation of high-quality aptamers for pharmaceutical applications.